According to filings with the U.S. Securities and Exchange Commission, LynkCare dba OncoLens is raising up to $14,964,529.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About LynkCare dba OncoLens
An AI driven oncology care platform that delivers next level multidisciplinary team collaboration, analytics and clinical decision support tools. The OncoLens platform: Integrates patient data across disparate data systems including EMRs, genomics, PACS, pathology and more. Extracts actionable informatics from structured and unstructured data to identify patients for clinical trials, biomarker testing, stem cell therapies and more. Enables multi-disciplinary care team collaboration within and across enterprises.

To learn more about LynkCare dba OncoLens, visit http://oncolens.com/
LynkCare dba OncoLens Linkedin Page: https://www.linkedin.com/company/oncolens/

Contact:
Anju Mathew, Chief Executive Officer
847-612-7895
https://www.linkedin.com/in/anju-mathew-045267/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.